Agenus Inc. (NASDAQ:AGEN) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET

Company Participants

Alexa Buffa - Corporate Communications
Garo Armen - Chairman and CEO
Steven O'Day - CMO
Robin Taylor - CCO
Christine Klaskin - VP of Finance

Conference Call Participants

Emily Bodnar - H.C. Wainright
Madeline Stone - William Blair

Operator

Good morning and welcome to Agenus' Third Quarter 2024 Conference Call and Webcast. All participants will be in a listen-only mode, until the question-and-answer session. Please note this event is being recorded. If anyone has any objections, you may disconnect at this time.

I would now like to turn the conference over to Alexa Buffa, from Agenus Corporate Communications. Alexa, please go ahead.

Alexa Buffa

Thank you operator, and thank you all for joining us today. Today's call is being webcast and will be available on our website for replay. I'd like to remind you that this call will include forward-looking statements, including statements regarding our clinical development, regulatory and commercial plans and timelines, as well as timelines for data release, and partnership opportunities among other updates. These statements are subjects to risks and uncertainties, and we refer you to our SEC filings available on our website for more details on these risks.

Joining me today are Dr. Garo Armen, Chairman and Chief Executive Officer; Dr. Robin Taylor, Chief Commercial Officer; and Christine Klaskin, Vice President of Finance. Dr. Steven O'Day, Chief Medical Officer will be participating in the question-and-answer session.

Now, I'd like to turn the call over to Garo, to highlight our progress in the third quarter.

Garo Armen

Thank you Alexa, and good morning everyone and thank you all for joining us today.

At Agenus, we are driven by the belief that we can redefine, what is possible in cancer treatment. This belief is embodied in the progress, we've made with BOT/BAL. BOT/BAL is showing unprecedented results, in cancers that have resisted all previous therapies, as well as in patients with earlier stages of disease, who face morbidities associated with conventional treatment options, such as chemotherapy, radiation and radical and sometimes debilitating, or even mutilating surgeries.

BOT/BAL represents a paradigm shift, in how we approach cancer treatment. In the neoadjuvant setting, for example, BOT/BAL has demonstrated the potential to address diseases such as MSS colorectal cancer, which do not typically respond to immunotherapy and, which account for more than 85% of all colorectal cancer.